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I-mfa has been identified as an inhibitor of myogenic basic helix-loop-helix transcription factors, and a
related human I-mfa domain-containing protein (HIC) also has been identified as a protein that regulates Tat-
and Tax-mediated expression of viral promoters. HIC and I-mfa represent a family of proteins that share a
highly conserved cysteine-rich domain, termed the I-mfa domain. We show here that both I-mfa domain
proteins, HIC and I-mfa, interacted in vivo with the Axin complex through their C-terminal I-mfa domains.
This interaction inhibited Axin-mediated downregulation of free levels of cytosolic -catenin. I-mfa and HIC
also both directly interacted with lymphocyte enhancer factor (LEF); however, I-mfa but not HIC significantly
inhibited reporter constructs regulated by -catenin. The overexpression of HIC but not I-mfa decreased the
inhibitory effects of Axin on -catenin-regulated reporter constructs, while both HIC and I-mfa decreased
Axin-mediated c-Jun N-terminal kinase (JNK) activation. These data reveal for the first time that I-mfa
domain proteins interact with the Axin complex and affect Axin regulation of both the Wnt and the JNK
activation pathways. Interestingly, HIC differs from I-mfa in that I-mfa affects both Axin function and T-cell
factor- or LEF-regulated transcription in the Wnt signaling pathway while HIC affects primarily Axin function.
The human I-mfa domain-containing protein (HIC) has
been identified as a protein that differentially regulates Tat-
and Tax-mediated expression of viral promoters: enhancing
expression from the human T-cell leukemia virus type 1 long
terminal repeat and repressing expression from the human
immunodeficiency virus type 1 long terminal repeat (30). HIC
contains a cysteine-rich C-terminal domain with a high degree
of homology to the C-terminal domain of I-mfa, termed an
I-mfa domain (30), and the regulatory properties of HIC de-
pend on this C-terminal domain. The I-mfa domain is also
required for I-mfa inhibition of MyoD and other related myo-
genic basic helix-loop-helix (bHLH) proteins by preventing
nuclear localization and DNA binding (6, 30). This similarity
suggests that HIC and I-mfa may have similar protein interac-
tions and properties (30). Indeed, I-mfa and XIC, the Xenopus
orthologue of HIC, were both found to bind to the HMG box
transcription factor Xtcf3 and to inhibit its DNA binding ac-
tivity (29). Thus, HIC and I-mfa likely represent a family of
proteins that share the I-mfa domain and regulate both bHLH-
dependent myogenic and Wnt signaling pathways.
The stabilization of -catenin is a key regulatory step during
development and tumorigenesis. Several proteins, including
glycogen synthase kinase 3 (GSK-3), the adenomatous polyp-
osis coli gene product (APC), disheveled (Dvl), and Axin, are
known to affect free -catenin protein levels within the cell (10,
11, 13, 14, 17, 22, 25). In the Wnt pathway, the Wnt ligand
protein binds the seven-membrane-spanning receptor protein,
frizzled, which then inhibits GSK-3-dependent phosphoryla-
tion of -catenin, resulting in the stabilization of -catenin (5,
25). The stable -catenin is transported to the nucleus, where
it interacts with transcription factors, including T-cell factor
(TCF) and lymphocyte enhancer factor (LEF) 1 (LEF-1), and
stimulates the expression of many Wnt target genes (4, 5). It is
unclear how Wnt signaling prevents -catenin phosphorylation
by GSK-3, although Dvl is implicated in this process (16).
Several mechanisms have been suggested, including a direct
inhibition of GSK-3 activity, inhibition of GSK-3 through the
interaction with GBP/Frat1, and dephosphorylation and desta-
bilization of Axin (19, 31). The scaffolding protein, Axin, forms
a complex with GSK-3, -catenin, APC, and Dvl through dis-
tinct binding sites (14, 22, 25). Within this complex, GSK-3
efficiently phosphorylates -catenin, and this phosphorylation
leads to the ubiquitination and proteasome-dependent degra-
dation of -catenin (9–11, 13). Thus, Axin negatively regulates
the Wnt signaling pathway (14, 15).
In addition to its role in Wnt signaling, the overexpression of
Axin also stimulates the c-Jun N-terminal kinase (JNK)/stress-
activated protein kinase (SAPK) signaling pathways (35). This
effect may require Axin homodimer formation and the direct
physical interaction of Axin with MEKK1 (34). GSK-3 inhib-
its Axin-mediated JNK activation, and this inhibition does not
require GSK-3 kinase activity. It has been suggested that
GSK-3 binding to Axin affects the Axin conformation, result-
ing in a block in MEKK binding (36).
In this report, we show that the I-mfa domain proteins HIC
and I-mfa interact in vivo with the Axin complex through their
I-mfa domains. This interaction requires the Axin GSK-3 bind-
ing site and results in increased levels of free -catenin. I-mfa
and HIC also directly bind to the human LEF-1 protein. I-mfa
and Axin both block the activation of TCF-mediated transcrip-
tion by -catenin, while HIC only slightly affects the activation
of TCF by -catenin but does partially reverse the inhibition by
Axin. In addition, both I-mfa and HIC decrease Axin-induced
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FIG. 1. HIC interacts with Axin in vivo. (A) Schematic representation of the Axin clone obtained from the yeast two-hybrid screening. Clone
C1-1, containing the middle of the -catenin binding site and encompassing the C-terminal portion of human Axin, interacted with the I-mfa
domain of HIC in a yeast two-hybrid system. The structural motifs of Axin are indicated as follows: RGS, the RGS domain; GSK3, GSK-3/
binding region; -Cat, -catenin binding region; PP2A, PP2A binding region; DIX, the DIX domain. (B) Schematic representation of the HIC and
I-mfa expression constructs with the three myc epitope tags at either the amino or the carboxy terminus and the deletion mutants lacking the
carboxy-terminal I-mfa domain. (C) Coimmunoprecipitation of HIC and Axin in vivo. COS-1 cells were transiently transfected with 0.5 g of
plasmid encoding HA-Axin and 0.5 g of plasmid encoding HIC-M3, M3-HIC, or M3-HICC. Immunoprecipitation (IP) was performed with HA
antibody-conjugated beads. (Left panel) Immunoblot analysis of total cell lysates with HA antibody to identify Axin or with anti-myc antibody to
identify HIC-M3, M3-HIC, or M3-HICC. (Right panel) Immunoblot analysis of immunoprecipitated complexes with HA antibody to identify
Axin or with anti-myc antibody to identify HIC-M3, M3-HIC, or M3-HICC. WB, Western blot. IP, immunoprecipitation.
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JNK activation. These findings indicate that I-mfa domain
proteins affect Axin regulation of both the Wnt and the JNK
signaling pathways and that HIC and I-mfa may differentially
affect these pathways.
MATERIALS AND METHODS
Materials. Antibody to -catenin was purchased from Transduction Labora-
tory, antibodies to GSK-3 and GSK-3 were purchased from StressGen, and
antibodies to myc (A-14), hemagglutinin (HA) (Y-11), JNK1 (FL), and phos-
phorylated JNK (G-7) were purchased from Santa Cruz Biotechnology. Western
blotting analysis was performed with Super Signal West Pico chemiluminescent
substrate (Pierce). myc epitope-tagged Xenopus -catenin, myc epitope-tagged
Xenopus GSK-3 (Xgsk3), and HA epitope-tagged human LEF-1 plasmids
were kindly provided by R. Moon (Howard Hughes Medical Institutes, Univer-
sity of Washington). The I-mfa cDNA was a gift from S. Tapscott (Fred Hutchin-
son Cancer Research Center, University of Washington), and the TOP-flash and
FOP-flash reporter plasmids were obtained from Upstate Biotechnology. PCR
amplification was performed with Platinum Pfx DNA polymerase (Life Technol-
ogies, Inc.) by using synthetic oligonucleotides synthesized at the Nucleic Acids
Core Facility of the University of North Carolina, Chapel Hill. The amplified
human lung cDNA library used for yeast two-hybrid screening was generously
provided by S. Milgram (University of North Carolina, Chapel Hill). All of the
DNA constructs were sequenced at the Automated DNA Sequencing Facility of
the University of North Carolina, Chapel Hill.
Construction of expression plasmids. HIC cDNA fragments were amplified by
PCR from a human lung cDNA library and cloned into pcDNA3 with three myc
epitopes at either the N terminus or the C terminus (Invitrogen). A deletion
mutant that lacked the C-terminal 82 amino acids representing the I-mfa domain
of HIC was constructed by KpnI-EcoRV digestion of the N-terminally tagged
HIC plasmid and cloned into KpnI-EcoRV-digested pcDNA3. The I-mfa domain
of the HIC cDNA fragment was amplified by PCR from the HIC plasmid and
cloned into pAS2-1 (Clontech) for expressing an in-frame fusion protein with a
GAL4 DNA binding domain. An N-terminal myc epitope-tagged form of I-mfa
was amplified by PCR from the I-mfa plasmid and cloned into pcDNA3. The
I-mfa domain deletion form was amplified by PCR from the N-terminal myc
epitope-tagged I-mfa cDNA and cloned into pcDNA3. N-terminal HA epitope-
tagged Axin (HA-Axin) cDNA was amplified by PCR from the human lung
cDNA library and cloned into pcDNA3.1/Zeo (Invitrogen). A set of C-termi-
nally truncated HA-Axin mutant cDNAs were amplified by PCR from the Axin
cDNA plasmid and cloned into pcDNA3.1/Zeo.
To express Axin and I-mfa domain proteins under inducible conditions for the
E-cadherin and free catenin assay, HA-Axin and myc-tagged I-mfa domain
proteins were cloned into pMEP4 (Invitrogen). Protein expression was induced
by 2.5 M CdCl2 for 12 h.
To express a glutathione S-transferase (GST)–E-cadherin fusion protein in
Escherichia coli, the -catenin binding region of human E-cadherin cDNA was
amplified by PCR from the human lung cDNA library and cloned into pGEX-
2TK (Amersham Pharmacia Biotech) as described previously (2). To express a
GST–I-mfa domain of HIC, the I-mfa domain of HIC was amplified by PCR
from the HIC cDNA and cloned into pGEX-3X.
Yeast two-hybrid screening. Yeast two-hybrid screening was performed as
previously described (18) by using the I-mfa domain of HIC (amino acids 165 to
246) as bait for human lung cDNA library screening.
Cell culturing and transfection. COS-1 and HEK-293 cells were maintained in
Dulbecco’s modified Eagle’s medium containing penicillin and streptomycin and
supplemented with 10% fetal bovine serum (Gibco BRL). COS-1 or HEK-293
cells at 1  106 (for immunoprecipitation or phosphorylated JNK analysis) or 5
 105 (for luciferase assay) were plated on 60-mm cell culture plates. Various
amounts of DNA were transfected by using Fugene 6 (Roche Molecular Bio-
chemicals) as suggested by the manufacturer.
Immunoprecipitation and Western blotting. At 48 h posttransfection, COS-1
cells were harvested and lysed in 3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate (CHAPS) lysis buffer containing a protease inhibitor cocktail
(Sigma). Protein concentrations were determined as previously described (18).
Lysates containing equal amounts of proteins were precleared with protein
A-Sepharose beads (Amersham Pharmacia Biochemical) for 1 h at 4°C and
immunoprecipitated with anti-HA affinity matrix (Roche Molecular Biochemi-
cal) for HA epitope-tagged proteins or anti-myc antibody 9E10-prebound pro-
tein A-Sepharose beads for myc epitope-tagged proteins. After 8 h at 4°C,
immune complexes were collected, washed three times in CHAPS lysis buffer,
and eluted in Laemmli sodium dodecyl sulfate (SDS) sample buffer. Proteins
were separated on SDS-polyacrylamide gels and then transferred to Immo-
bilon-P (Millipore). Western blotting was carried out with various antibodies as
previously described (18).
In vitro translation and GST binding. GST or GST–I-mfa domain proteins
were expressed in DH5 induced with 0.2 mM isopropyl--D-galactopyranoside
(IPTG) at room temperature. The cells were pelleted and lysed by sonication in
phosphate-buffered saline (PBS) containing 1% Triton X-100, 1 mM phenyl-
FIG. 2. I-mfa binds to Axin in vivo. COS-1 cells were transiently transfected with 0.5 g of plasmid encoding HA-Axin and 0.5 g of plasmid
encoding M3-I-mfa or M3-I-mfaC. This step was followed by immunoprecipitation (IP) for Axin with HA antibody-conjugated beads. (A) Im-
munoblot analysis of total cell lysates with HA antibody to identify Axin or with anti-myc antibody to identify M3-I-mfa or M3-I-mfaC.
(B) Immunoblot analysis of immunoprecipitated complexes with HA antibody to identify Axin or with anti-myc antibody to identify M3-I-mfa or
M3-I-mfaC.
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FIG. 3. The interaction of HIC with Axin requires the GSK-3 binding domain of Axin. (A) Schematic representation of the truncated Axin
mutants. Structural motifs of Axin are indicated as described in the legend to Fig. 1. (B) Coimmunoprecipitation of HIC and C-terminally
truncated Axin mutants in vivo. COS-1 cells were transiently transfected with 0.03 g of plasmid encoding Xgsk3, 1 g of plasmid encoding
M3-HIC, and 0.6 g of plasmid encoding each of the HA epitope-tagged C-terminally truncated Axin mutants. Immunoprecipitation (IP) was
carried out with HA antibody-conjugated beads. (Left panel) Immunoblot analysis of total cell lysates with anti-myc antibody to identify Xgsk3
and M3-HIC or with HA antibody to identify the C-terminally truncated Axin mutants. (Right panel) Immunoblot analysis of immunoprecipitated
Axin complexes with anti-myc antibody to identify Xgsk3 and M3-HIC or with HA antibody to identify the C-terminally truncated Axin mutants.
WB, Western blot. (C) Reciprocal coimmunoprecipitation of HIC and C-terminally truncated Axin mutants in vivo. COS-1 cells were transiently
transfected with 0.4 g of plasmid encoding M3-HIC and 1 g of plasmid encoding each of the HA epitope-tagged C-terminally truncated Axin
mutants. Immunoprecipitation was carried out with myc antibody-prebound protein A-Sepharose. (Left panel) Immunoblot analysis of total cell
lysates with anti-myc antibody to identify M3-HIC or with HA antibody to detect the C-terminally truncated Axin mutants. (Right panel)
Immunoblot analysis of immunoprecipitated HIC-containing complexes with anti-myc antibody to identify M3-HIC or with HA antibody to identify
the C-terminally truncated Axin mutants. (D) Coimmunoprecipitation of HIC and N-terminally truncated Axin mutants in vivo. COS-1 cells were
transiently transfected with 0.5 g of plasmid encoding M3-HIC and 1 g of plasmid encoding each of the HA epitope-tagged N-terminally
truncated Axin mutants. Immunoprecipitation was carried out with myc antibody-prebound protein A-Sepharose. (Left panel) Immunoblot
analysis of total cell lysates with anti-myc antibody to identify M3-HIC or with HA antibody to identify the N-terminally truncated Axin mutants.
(Right panel) Immunoblot analysis of immunoprecipitated HIC-containing complexes with anti-myc antibody to identify M3-HIC or with HA
antibody to identify the N-terminally truncated Axin mutants.
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methylsulfonyl fluoride, and 5 g of aprotinin/l on ice. Bacterial lysates were
clarified by centrifugation, and the GST or GST–I-mfa domain proteins were
purified by binding to glutathione-Sepharose beads (Amersham Pharmacia Bio-
tech) for 1 h at 4°C. The beads were washed three times and then resuspended
in PBS containing 1% Triton X-100. Axin and C-terminally truncated Axin
mutants were transcribed and translated in vitro by using a TNT T7 coupled
reticulocyte lysate system (Promega) as recommended by the manufacturer. The
in vitro-translated products were diluted in PBS containing 1% Triton X-100 and
mixed with GST or GST–I-mfa. After incubation for 2 h at 4°C, the beads were
collected by centrifugation and washed three times. Proteins were eluted in
Laemmli SDS sample buffer, subjected to SDS-polyacrylamide gel electrophore-
sis (PAGE), and analyzed by using a phosphorimager.
GST–E-cadherin pull-down assay. GST or GST–E-cadherin protein was
expressed in DH5 induced with 0.5 mM IPTG at 37°C. Cells were pelleted,
resuspended in ice-cold PBS, and lysed by sonication in E-cadherin lysis
buffer (10 mM sodium phosphate [pH 7.4], 150 mM NaCl, 1% Nonidet P-40,
2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 g of aprotinin/ml) on
ice. Bacterial lysates were clarified by centrifugation, and GST or GST–E-
cadherin was purified by binding to glutathione-Sepharose beads for 1 h at
4°C. The beads were washed three times and resuspended in E-cadherin lysis
buffer. At 48 h posttransfection, COS-1 cells were harvested and lysed in
E-cadherin lysis buffer containing a protease inhibitor cocktail for 30 min at
4°C. Protein concentrations in lysates were quantitated. Protein lysates (100
g) were precleared with GST-bound Sepharose beads for 45 min at 4°C and
incubated with Sepharose beads bound to GST–E-cadherin. After 1 h of
incubation at 4°C, the beads were collected and washed three times by
centrifugation. Proteins were eluted in Laemmli SDS sample buffer, sepa-
rated on SDS-polyacrylamide gels, and then transferred to Immobilon-P.
Western blotting was carried out with various antibodies as previously de-
scribed (18).
Luciferase assay. At 72 h posttransfection, COS-1 cells were harvested and
lysed in Glo lysis buffer (Promega). Protein concentrations in lysates were de-
termined. Luciferase activities in equal volumes of lysates were analyzed as
suggested by the manufacturer. Luminescence intensities were normalized
against protein concentrations.
Western blotting of active JNK. At 48 h posttransfection, HEK-293 cells were
harvested and lysed in radioimmunoprecipitation buffer containing a protease
inhibitor cocktail and phosphatase inhibitor cocktail I (Sigma). Protein concen-
trations of lysates were determined as previously described (18). Equal amounts
of proteins were subjected to SDS-PAGE and then transferred to Immobilon-P.
Levels of activated JNK were analyzed with the phosphorylated JNK antibody
G-7. Total JNK levels were analyzed by using the same membrane and a JNK1
antibody (FL) following stripping of the phosphorylated JNK antibody.
RESULTS
HIC interacts with Axin through its I-mfa domain. I-mfa
was identified as a protein that interacts with and inhibits the
activity of MyoD and related myogenic bHLH proteins
through its C-terminal I-mfa domain (6). Although HIC also
regulates transcription, it does not directly interact with myo-
genin or MyoD (unpublished data). To identify a cellular tar-
get protein of HIC, a human lung cDNA library was screened
by using the yeast two-hybrid method with the I-mfa domain of
HIC (amino acids 165 to 246) as bait. Approximately 6  105
transformants were tested for growth on selection medium and
-galactosidase induction. Sequence analysis of a positive
clone revealed that the cDNA represented the C-terminal por-
tion of human Axin (amino acids 505 to 900) (33). This clone
contained part of the -catenin binding site and spanned the C
terminus of human Axin (12) (Fig. 1A).
To test the interaction between the I-mfa domain of HIC
and Axin in vivo, HA-Axin and N-terminal myc epitope-tagged
HIC (M3-HIC), N-terminal myc epitope-tagged truncated
HIC with a deletion of the I-mfa domain (M3-HICC), or
C-terminal myc epitope-tagged HIC (HIC-M3) were coex-
pressed in COS-1 cells (Fig. 1B). Immunoblotting of the total
lysates indicated equivalent expression of all constructs (Fig.
1C). However, immunoprecipitation with HA antibody-conju-
gated beads to precipitate Axin revealed that M3-HIC was
efficiently coimmunoprecipitated with HA-Axin (Fig. 1C, lane
15) and that deletion mutant M3-HICC was not coimmuno-
precipitated (Fig. 1C, lane 16). The carboxy-terminal tagged
form, HIC-M3, was less efficiently precipitated, possibly due to
the effects of the C-terminal epitope tag on the protein-protein
interaction between Axin and the C-terminal I-mfa domain of
HIC. Immunoprecipitation of M3-HIC with myc antibody-con-
jugated beads also coprecipitated HA-Axin, while that of M3-
HICC did not (data not shown). These observations revealed
that HIC binds to Axin in vivo and that the I-mfa domain of
HIC is necessary for this interaction.
FIG. 4. The direct interaction of in vitro-translated Axin with a GST–I-mfa fusion protein requires C-terminal amino acids. Plasmids (1 g
each) encoding Axin and mutants were transcribed and translated in vitro in the presence of [35S]methionine. (A) In vitro-translated products (3
l) were subjected to SDS-PAGE. The gel was dried and exposed to film. (B) In vitro-translated products (20 l) were diluted in 330 l of PBS
containing 1% Triton X-100 and incubated with GST- or GST–I-mfa-bound beads for 2 h at 4°C. The beads were washed three times with PBS
containing Triton X-100. The proteins were eluted from the beads into SDS sample buffer and subjected to SDS-PAGE.
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I-mfa also binds to Axin. As the I-mfa domains of HIC and
I-mfa are highly homologous, with 77% identity and 81% sim-
ilarity (30), the possible interaction between I-mfa and Axin
was tested in vivo. I-mfa with three myc epitope tags at the
amino terminus (M3-I-mfa) or I-mfa with a deletion of the
I-mfa domain (M3-I-mfaC) was coexpressed with HA-Axin
in COS-1 cells. Immunoprecipitation analysis with HA anti-
body-conjugated beads revealed that M3-I-mfa but not M3-I-
mfaC was efficiently coimmunoprecipitated with HA-Axin
(Fig. 2B, lanes 5 and 6). This result indicated that I-mfa also
interacts with Axin in vivo through its I-mfa domain.
Axin and I-mfa domain proteins interact through the GSK-3
binding domain in vivo. Axin is known to a make a multipro-
tein complex with APC bound to the N-terminal RGS domain
and GSK-3, -catenin, and protein phosphatase 2A (PP2A)
binding to the central part of Axin. The C-terminal DIX do-
main is responsible for binding to Dvl and enabling ho-
modimer formation (28) (Fig. 3A).
C-terminally or N-terminally truncated mutants of human
Axin were synthesized and tested for binding to HIC in COS-1
cells. Although all of the proteins were efficiently expressed,
immunoblot analysis of immunoprecipitated full-length or C-
terminally truncated mutants of Axin complexes indicated that
the the Axin mutant with a deletion of amino acids 1 to 384
(1–384 Axin mutant) was not coprecipitated with HIC (Fig. 3B,
lane 18), although full-length Axin and other C-terminally
truncated Axin mutants were coprecipitated with HIC (Fig.
3B, lanes 13 to 17). These results suggested that amino acids
385 to 468 of Axin, which are thought to represent the GSK-3
binding domain, are required for the interaction with HIC. To
confirm that amino acids 385 to 468 of Axin represent the
GSK-3 binding domain, the Axin mutants were tested for in-
teractions by coprecipitation with Xgsk3. Similar to the in-
teraction with HIC, the 1–384 Axin mutant was not coprecipi-
tated with Xgsk3 (Fig. 3B, lane 18), while full-length Axin and
other C-terminally truncated mutants of Axin efficiently inter-
acted (Fig. 3B, lanes 13 to 17). These results indicated that
amino acids 385 to 468 of Axin are required for the interaction
between the Axin complex and HIC and for the interaction
between Axin and GSK-3. The interaction between I-mfa and
Axin mutants was also tested. Similar to the results obtained
with HIC, I-mfa did not bind to the 1–384 Axin mutant but did
bind to full-length Axin and other C-terminally truncated Axin
mutants (data not shown). These observations indicated that
the interaction of I-mfa domain proteins with the Axin com-
plex requires the GSK-3 binding-site of Axin.
The interaction between HIC and C-terminally truncated
mutants of Axin was confirmed in a reciprocal immunoprecipi-
tation with myc antibody-prebound protein A-Sepharose beads
to precipitate HIC. Immunoblot analysis of immunoprecipi-
FIG. 5. C-terminally truncated Axin complexes interact with HIC in vivo and contain GSK-3 and -catenin. COS-1 cells were transiently
transfected with 1 g of plasmid encoding the 1–724 Axin mutant and 1 g of plasmid encoding M3-HIC or MC-HICC. (A) Immunoblot analysis
of total cell lysates with HA antibody to identify the 1–724 Axin mutant, with anti-myc antibody to identify M3-HIC and MC-HICC, with
-catenin antibody to identify endogenous -catenin, or with GSK-3 antibody to identify endogenous GSK-3 and GSK-3. (B) Immunoblot
analysis of precipitated material to identify Axin, -catenin, GSK-3, and GSK-3 in the HIC-containing complexes.
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tated HIC-containing complexes confirmed that the 1–384
Axin mutant was not coprecipitated with HIC (Fig. 3C, lane
16), while full-length Axin and other C-terminally truncated
Axin mutants were efficiently coprecipitated (Fig. 3C, lanes 11
to 15).
Although amino acids 385 to 468 of Axin were clearly re-
quired for the interactions of HIC and I-mfa with Axin in vivo,
these sequences were not contained in the cDNA clone, C1-1,
which was isolated from the yeast two-hybrid screening (Fig.
1A). This result suggested that the C terminus of Axin may
contain an additional site for interactions with HIC. Therefore,
N-terminally truncated mutants of Axin were also tested for
interactions with HIC. Immunoblot analysis of immunopre-
cipitated HIC-containing complexes revealed that full-length
Axin and the 385–900 Axin mutant were efficiently coprecipi-
tated with HIC (Fig. 3D, lanes 10 and 11), while the 469–900
Axin mutant was very faintly detected (Fig. 3D, lane 12). These
results confirmed that amino acids 385 to 468 of Axin not only
represent the GSK-3 binding site but also are required for
significant interactions between the Axin complex and I-mfa
domains in vivo. The weak interaction of the 469–900 Axin
mutant with HIC suggested a possible secondary binding site.
This region of Axin was contained within the clone identified in
the yeast two-hybrid screening.
Direct interaction between HIC and Axin. The Axin complex
contains binding sites for multiple proteins, and the binding of
some proteins has been suggested to affect the Axin confor-
mation. To determine if there was a direct interaction between
Axin and the I-mfa domain of HIC, the I-mfa domain of HIC
was fused to GST, and Axin and the C-terminally truncated
forms of Axin (Fig. 3A) were translated in vitro. Axin and the
deletion mutants were translated with equivalent efficiencies
and bound at trace levels to GST (Fig. 4). The GST–I-mfa
domain fusion protein bound approximately 20% of the total
input of full-length Axin (amino acids 1 to 900), while the
1–824 Axin mutant showed some residual binding. The 1–724
Axin mutant and other C-terminally truncated forms bound
GST–I-mfa at levels equivalent to the level of nonspecific bind-
ing to GST. These results confirmed that, in vitro, Axin directly
interacts with the I-mfa domain through the C-terminal 157
amino acids of Axin, sequences that were present in the clone
isolated from the yeast two-hybrid screening.
As immunoprecipitation of full-length HIC did not immu-
noprecipitate C-terminally truncated mutants of Axin that did
not interact in vitro with the I-mfa domain (Fig. 3C), the
interactions of HIC and HIC lacking the I-mfa domain
(HICC) with the 1–724 Axin mutant, which lacks the I-mfa
interaction domain identified in vitro, were tested in vivo by
immunoprecipitation (Fig. 5). The 1–724 Axin mutant could
interact only with full-length HIC and not with HICC. These
data confirmed that, in vivo, HIC can form a complex with
Axin that lacks the sequences that directly interact with the
HIC I-mfa domain in vitro and that this interaction requires
the HIC I-mfa domain. These data suggested that the confor-
mation of the Axin complex in vivo, when it is bound to addi-
tional proteins, enables the binding of the HIC I-mfa domain
to the Axin complex and that this binding requires the GSK-3
binding site. Identification of other proteins in the HIC-Axin
complex revealed that endogenously expressed GSK-3, GSK-
3, and -catenin were also present in the immunoprecipitated
FIG. 6. I-mfa domain proteins HIC and I-mfa increase the free levels of -catenin in the presence of Axin. COS-1 cells were transiently
transfected with 1.0 g of plasmid pMep4 encoding HA-Axin and 1.0 g of plasmid encoding M3-HIC, M3-HICC, M3-I-mfa, or M3-I-mfaC.
Cytosolic free -catenin was precipitated from cytosolic cell lysates with a GST–E-cadherin fusion protein. Immunoblot analysis of 20 g of
cytosolic cell lysates was done with HA antibody to identify Axin, with anti-myc antibody to identify HIC and I-mfa, or with -catenin antibody
to identify the total levels of -catenin and free -catenin bound to the GST–E-cadherin fusion protein.
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HIC-containing complex but not in the immunoprecipitated
complex with HICC (Fig. 5). These proteins were not immu-
noprecipitated with HIC in the absence of Axin, indicating that
GSK-3 and -catenin do not directly interact with HIC, as their
presence in the immunoprecipitated complex required Axin.
The simultaneous binding of HIC and GSK-3 also apparently
does not result from Axin dimerization, as the 1–743 Axin
mutant has a deletion of the dimerization domain. These data
suggested that HIC and GSK-3 may bind simultaneously to the
same site of Axin or that the interaction with the Axin complex
in vivo is indirect and possibly requires GSK-3 in the complex.
HIC increases free -catenin levels in the presence of Axin.
Axin is known to enhance the phosphorylation of -catenin by
GSK-3 and to decrease the level of free -catenin (14). To
detect free -catenin, the C-terminal (-catenin binding) do-
main of E-cadherin fused to GST was used to bind free -cate-
nin in cell lysates (24). The overexpression of Axin decreased
the level of free -catenin as previously described (data not
shown). The coexpression of HIC or I-mfa with Axin increased
the level of free -catenin (Fig. 6), while the noninteracting
HICC and I-mfa with a deletion of the I-mfa domain (I-
mfaC) did not affect the level of free -catenin. Although the
data presented in Fig. 5 suggested that HIC apparently does
not displace -catenin from the Axin complex, HIC apparently
can affect the function of the Axin complex, resulting in an
increase in the level of free -catenin.
HIC and I-mfa differentially regulate Wnt signaling. Free
-catenin activates the expression of Wnt-regulated genes
through its interaction with the TCF and LEF transcription
factors. However, I-mfa has been shown to inhibit the activity
and DNA binding of the Xenopus TCF homologue, Xtcf3 (29).
To determine the effects of the I-mfa domain proteins HIC and
I-mfa on the Wnt signaling pathway, the ratio of the activity of
a -catenin-responsive promoter containing TCF binding sites
(TOP-flash) to the activity of a promoter containing mutated
TCF binding sites (FOP-flash) was determined in the presence
of I-mfa or HIC. The expression of -catenin increased the
ratio of TOP-flash activity to FOP-flash activity approximately
10-fold, and this ratio was considered 100% activity (Fig. 7). As
previously shown, Axin or I-mfa significantly decreased -cate-
nin activation of TCF-mediated transcription (Fig. 7, lanes 6
and 4). In contrast, HIC did not consistently decrease -cate-
nin activation of the TCF promoter (Fig. 7, lane 2) but did
partially block the ability of Axin to repress -catenin activa-
tion of TCF-mediated transcription (Fig. 7, lane 7). This effect
was dependent on the I-mfa domain of HIC, suggesting that a
direct protein-protein interaction is required. Importantly,
these data revealed that the I-mfa domain proteins HIC and
I-mfa have distinct effects on Wnt signaling.
I-mfa binds to LEF-1 more efficiently than HIC in vivo. In
agreement with the data presented here, it was previously
shown that I-mfa inhibits the activity and DNA binding of the
Xenopus homologue of TCF, Xtcf3 (29). To determine
whether HIC and I-mfa directly interact with human TCF or
LEF, HA-tagged human LEF-1 (HA-LEF-1) and M3-HIC,
M3-HICC, M3-I-mfa, or M3-I-mfaC were coexpressed in
COS-1 cells. Immunoblotting of the total cell lysates indicated
that all of the constructs were expressed, with approximately
equal levels of HIC and I-mfa (Fig. 8A), and approximately
equal amounts of HIC and I-mfa were present in the immu-
noprecipitated complexes (Fig. 8B). Immunoblotting of the
immunoprecipitated I-mfa and HIC protein complexes re-
vealed that HIC and I-mfa both interacted with LEF-1 (Fig.
8B, lanes 7 and 9), while the deletion forms, HICC and
I-mfaC, did not (Fig. 8B, lanes 8 and 10). These observations
are consistent with the previous finding that I-mfa binds to
Xtcf3 through its I-mfa domain (29). However, the amount of
LEF-1 detected in the precipitated I-mfa complex was consid-
erably larger than that detected in the HIC-containing complex
(Fig. 8B, lanes 7 and 9). These results suggested that both
I-mfa domain proteins, HIC and I-mfa, bind to LEF-1 in vivo
FIG. 7. I-mfa but not HIC inhibits -catenin-responsive synthetic
TCF promoter activity. COS-1 cells were transiently transfected with 1
g of TOP-flash or FOP-flash plasmid; 0.2 g of plasmid encoding
Xenopus -catenin, 0.3 g of plasmid encoding HA-Axin, or vector
pcDNA3.1/Zeo; and 0.7 g of plasmid encoding M3-HIC, M3-
HICC, M3-I-mfa, or M3-I-mfaC or vector pcDNA3. At 72 h after
transfection, cells were lysed and luciferase activities were determined.
The TOP-flash/FOP-flash activity ratio is represented as 100% for
vector plus -catenin. The average relative value from four experi-
ments is presented for M3-HIC, M3-HICC, M3-I-mfa, and M3-I-
mfaC; error bars indicate standard deviations.
VOL. 22, 2002 I-mfa DOMAIN PROTEINS INTERACT WITH AXIN 6401
but that the binding affinity of I-mfa is apparently greater than
that of HIC.
I-mfa domain proteins inhibit Axin-mediated JNK activa-
tion. It was previously shown that Axin activates the JNK pathway
and that GSK-3 inhibits Axin-mediated JNK activation (34, 35).
This inhibition of JNK activation by GSK-3 does not require
GSK-3 kinase activity but does require the binding of GSK-3,
apparently blocking the binding of MEKK to Axin (36). As HIC
and I-mfa interact with the GSK-3 binding domain of Axin, it
was of interest to determine whether either I-mfa domain protein
affected Axin-mediated JNK activation. The expression of HA-
Axin in HEK-293 cells efficiently stimulated the phosphorylation
of JNK1 and JNK2 (Fig. 9B, lanes 1 and 6). However, the coex-
pression of HIC or I-mfa with Axin decreased the levels of acti-
vated JNK1 and JNK2 (Fig. 9B, lanes 7 and 9), while the coex-
pression of HICC or I-mfaC with Axin did not affect the levels
of activated JNK1 and JNK2 (Fig. 9B, lanes 8 and 10). Reprobing
of the same membrane with an antibody that recognizes both
phosphorylated JNK and unphosphorylated JNK indicated that
the levels of total JNK1 and JNK2 in the lysates were identical
(Fig. 9C). These results indicated that the presence of the I-mfa
domain proteins HIC and I-mfa in the Axin complex decreases
Axin-mediated JNK activation and that the I-mfa domains are
necessary for this effect.
DISCUSSION
Axin was first identified as the product of the mouse gene
Fused and plays a critical role in the regulation of embryonic
axis formation (33). Mutations of Axin have been reported for
hepatocellular carcinoma, suggesting that Axin also plays an
important role in the tumor development process in addition
to its role in embryonic axis formation (27). Axin is a scaffold-
ing protein that binds to GSK-3, -catenin, APC, Dvl, and
PP2A and enhances GSK-3-dependent phosphorylation of
-catenin (10–14, 16, 17, 22). The phosphorylation of -catenin
targets it for ubiquitination and proteasome-dependent degra-
dation, resulting in low levels of cytosolic free -catenin and no
activation of TCF- or LEF-regulated transcription (Fig. 10)
(1). The mechanism by which Wnt ligand binding inhibits
GSK-3 is unknown; however, the Dvl protein, which also binds
Axin, affects this process, resulting in the accumulation of free
-catenin and the activation of transcription of target genes
through -catenin interactions with the TCF and LEF tran-
scription factors (3, 7, 8, 19, 21, 26, 32).
The data presented here reveal for the first time that the
I-mfa domain proteins HIC and I-mfa directly interact with
Axin in vitro and that the I-mfa domain of each protein is
necessary for these interactions. The identification of the
GSK-3 binding site sequences as the specific Axin sequences
required for the interactions with HIC and I-mfa in vivo was
surprising, as these sequences were not contained in the
Axin cDNA clone (containing the C-terminal portion of
Axin) that was isolated from the yeast two-hybrid screening
with the I-mfa domain of HIC. However, the C-terminal
region of Axin was required for the direct interaction of in
vitro-translated Axin with the I-mfa domain. These data
suggested that the conformation of Axin is altered in vivo
when Axin is present in complexes with additional proteins.
The binding of HIC and I-mfa to the Axin complex may be
indirect. The clear requirement for the GSK-3 binding site
may indicate that the appropriate conformation of the Axin
complex for interactions with HIC and I-mfa requires
GSK-3 in the complex. The finding that the expression of
either HIC or I-mfa did not affect the binding of GSK-3 to
Axin is similar to that of a recent study indicating that
low-density lipoprotein receptor-related protein 5 also in-
FIG. 8. I-mfa binds LEF-1 more effectively than HIC in vivo. COS-1 cells were transiently transfected with 0.8 g of plasmid encoding
HA-LEF-1 and 0.8 g of plasmid encoding M3-HIC, M3-HICC, M3-I-mfa, or M3-I-mfaC. Immunoprecipitation (IP) of 300 g of total cell
lysates was performed with myc antibody-prebound protein A-Sepharose. (A) Immunoblot analysis of 20 g of total cell lysates with HA antibody
to identify HA-LEF-1 or with anti-myc antibody to identify M3-HIC, M3-HICC, M3-I-mfa, or M3-I-mfaC. (B) Immunoblot analysis of
immunoprecipitated I-mfa and HIC-containing complexes with anti-myc antibody to identify M3-HIC, M3-HICC, M3-I-mfa, or M3-I-mfaC or
with HA antibody to identify HA-LEF-1.
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teracts with the GSK-3 binding domain of Axin without
stoichiometric effects on the Axin–GSK-3 complex (20).
I-mfa was previously shown to inhibit TCF-mediated tran-
scription through its interaction with TCF and its inhibition of
TCF DNA binding (29). In this study, I-mfa but not HIC
expression decreased -catenin activation of TCF transcription
(Fig. 7). These data suggested that HIC primarily targets and
blocks Axin function, while I-mfa can negatively regulate both
Axin and TCF and LEF activities. The negative regulation by
I-mfa of Wnt signaling in development has been demonstrated
in vivo by injection of I-mfa into Xenopus embryos, blocking
Wnt-mediated axis duplication (29). I-mfa may primarily neg-
atively regulate Wnt signaling through its inhibition of TCF- or
LEF-mediated transcription, while HIC may have positive ef-
fects on the Wnt pathway through its inhibitory effects on
Axin-mediated repression (Fig. 10).
An additional property of Axin is its stimulation of JNK/
SAPK signaling through its effects on MEKK1 function, and it
is known that the stimulation of JNK signaling is inhibited by
the binding of GSK-3 to Axin (35). As this inhibition does not
require GSK-3 kinase activity, the binding of GSK-3 to Axin
apparently induces a conformational change in Axin that does
not permit MEKK1 binding to Axin and the resultant MEKK1
activation (36). This finding suggested that distinct Axin com-
plexes either can activate MEKK1 and JNK or can negatively
regulate Wnt signaling (Fig. 10). The data presented here
indicate that the I-mfa domain proteins HIC and I-mfa de-
crease Axin-mediated JNK activation through their interaction
with the GSK-3 binding site of Axin. These observations may
indicate that I-mfa domain proteins possibly induce or pre-
serve the conformational changes in Axin that prevent
MEKK1 binding to Axin and possibly also repress the function
or formation of the Axin–GSK-3–-catenin complex. Conse-
quently, the I-mfa domain proteins increase the cytosolic levels
of free -catenin in the presence of Axin and decrease Axin-
mediated JNK activation.
Axin has been shown to induce apoptosis in certain cell types
due to its effects on -catenin stability and JNK activation (23).
Therefore, the I-mfa domain proteins HIC and I-mfa could
protect from Axin-induced apoptosis, possibly indicating a role
in cell survival. However, I-mfa has complex properties and can
also inhibit both myogenic bHLH proteins and LEF and TCF
transcription factors. In contrast, HIC does not bind to myo-
genic bHLH proteins and does not have significant inhibitory
effects on synthetic TCF promoter activity. These results sug-
gest that the primary functions of HIC may be to regulate Axin
and possibly to contribute to cell survival.
FIG. 9. HIC and I-mfa decrease Axin-mediated JNK activation. HEK-293 cells were transiently transfected with 1 g of plasmid encoding
HA-Axin and 1 g of plasmid encoding M3-HIC, M3-HICC, M3-I-mfa, or M3-I-mfaC. (A) Immunoblot analysis of 20 g of total cell lysates
with HA antibody to determine the expression of transfected HA-Axin. (B) Immunoblot analysis with antibody (Ab) to phosphorylated JNK
(phospho-JNK) to determine the levels of activated JNK1 and JNK2. (C) Immunoblot analysis of the same membrane as that used in panel B after
stripping of the phospho-JNK antibody and reprobing with JNK1 antibody to identify the levels of total JNK1 and JNK2.
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